TABLE 1.
Responses to provider satisfaction surveys
| n | % | |
|---|---|---|
| Patient characteristics (N = 81) | ||
| Patient gender | ||
| Female | 46 | 42 |
| Male | 34 | 57 |
| Other | 1 | 1 |
| Patient age (years) | ||
| <18 | 28 | 35 |
| 18–29 | 31 | 38 |
| 30+ | 22 | 27 |
| Diagnostic category | ||
| Hematological malignancy | 50 | 62 |
| Solid tumor | 27 | 33 |
| Other | 4 | 5 |
| Visit characteristics (n = 94) | ||
| Week of visit | ||
| 1–5 | 31 | 33 |
| 6–7 | 27 | 29 |
| 8–10 | 36 | 38 |
| Provider VV volume* | ||
| Low (<10 VV) | 4 | 57 |
| High (20–30 VV) | 3 | 43 |
| Risk for late effects ¥ | ||
| Low | 29 | 31 |
| Moderate | 29 | 31 |
| High | 36 | 38 |
| Visit content† | ||
| Late effects and recommended follow‐up | ||
| Focal topic | 77 | 82 |
| Nonfocal topic | 14 | 15 |
| COVID‐related symptom | ||
| Focal topic | 36 | 38 |
| Nonfocal topic | 36 | 38 |
| Psychological well‐being | ||
| Focal topic | 22 | 23 |
| Non‐focal topic | 71 | 76 |
| Symptom (treatment related) | ||
| Focal topic | 20 | 21 |
| Non‐focal topic | 10 | 11 |
| Symptom (not treatment related) | ||
| Focal topic | 14 | 15 |
| Nonfocal topic | 27 | 29 |
| Concern about recurrence | ||
| Focal topic | 6 | 6 |
| Nonfocal topic | 17 | 18 |
| Follow‐up | ||
| Follow‐up imaging/laboratory tests | ||
| Urgently | 4 | 4 |
| At next follow‐up | 15 | 16 |
| As soon as restrictions are lifted | 67 | 71 |
| None | 8 | 9 |
| Follow‐up visit plan‡ | ||
| Urgent evaluation | 7 | 7 |
| Nonurgent PCP | 9 | 10 |
| Survivor clinic as soon as restrictions lifted | 12 | 13 |
| Survivor clinic at regular visit interval | 68 | 72 |
| Other medical specialist | 9 | 10 |
| Satisfaction | ||
| Overall satisfaction | ||
| Completely | 35 | 37 |
| Very | 46 | 49 |
| Moderately | 10 | 11 |
| Slightly | 3 | 3 |
| Not at all | 0 | 0 |
| Met clinical care objectives | ||
| Yes | 42 | 45 |
| No | 51 | 54 |
Abbreviations: PCP, primary care provider; VV, virtual visit.
*Four providers with <10 VV classified as low volume; three providers with >20–30 VV classified as high volume.
¥Provider rated late‐effect risk as high (i.e., treated with radiation, stem cell transplant, high‐dose alkylators or anthracyclines >250 mg/m2; current surveillance for any cancer; recent onset or multiple late effects; hereditary cancer predisposition), moderate (i.e., anthracyclines <250 mg/m2, low‐dose alkylators, age <25 years, off therapy <10 years, any psychosocial morbidity), or low (i.e., all others).
†Topics that were a visit focus rated as “focal”; other topics discussed rated “non‐focal”; topics rated “not discussed” are not shown.
‡% total to >100% as participants were able to select multiple responses.